Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
December 20, 2022 19:01 ET
|
Sosei Group Corporation
PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10...
Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 01:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41st...
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 15, 2022 19:01 ET
|
Sosei Group Corporation
New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2022
November 11, 2022 01:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Orion Biotechnology to Attend the LSX Investival Showcase and Jefferies Healthcare Conference
November 10, 2022 09:03 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously...
Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2022
November 09, 2022 03:00 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill and Matt Barnes, Head of UK...
Orion Biotechnology to present at 2022 Dr. GPCR Summit Conference
October 11, 2022 09:03 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...
Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum
September 27, 2022 02:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The...
Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan
September 01, 2022 19:05 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in...
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2022
August 10, 2022 02:45 ET
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its...